MINNEAPOLIS, Minnesota – August 7, 2018 – Inspire Medical Systems, Inc. (NYSE: INSP)
(“Inspire”), a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), reported
financial results for the quarter ended June 30, 2018.
Recent Business Highlights
- Revenues of $10.9 million in the second quarter of 2018, an 81% increase over the same quarter last
year and provides full year 2018 revenue guidance to be in a range of $42.8 million to $44.0 million
- Activated 15 new U.S. medical centers in the second quarter of 2018, bringing the total to 168 U.S.
medical centers implanting Inspire therapy
- Aetna issued a policy decision to provide coverage to its approximately 22 million members for
- Received approval from Japan’s Ministry of Health, Labour and Welfare for Inspire therapy to treat
moderate to severe OSA in Japan
“We are extremely pleased with our continued strong growth in revenues in the second quarter,” said Tim
Herbert, President and Chief Executive Officer of Inspire Medical Systems. “These results demonstrate
the strong and growing adoption of Inspire therapy by physicians and patients as a highly differentiated
solution for the treatment of moderate to severe obstructive sleep apnea. In order to drive further growth,
we are focused on increasing patient flow at existing medical centers, training and activating new medical
centers, and adding territory managers in the U.S.”
“We were also excited to recently receive a positive national coverage decision for Inspire therapy from
Aetna, a leading U.S. health plan that provides coverage for approximately 22 million members,”
continued Mr. Herbert. “The team continues to focus on establishing reimbursement, both with positive
coverage policies as well as supporting centers on obtaining individual prior authorization approvals.”
Second Quarter 2018 Financial Results
Revenue was $10.9 million in the three months ended June 30, 2018, an 81% increase from $6.0 million
in the three months ended June 30, 2017. The increase in sales of our Inspire system reflects greater
market penetration in existing territories, expansion into new territories and increased physician and
Gross profit was $8.8 million for the second quarter of 2018, an increase of 89% from $4.7 million in the
corresponding prior year period. Gross margin was 81%, as compared to 77% in the corresponding prior
year period. The gross margin improvement was primarily due to an excess inventory charge of the
previous generation system in the second quarter of 2017 in anticipation of the U.S. commercial release of
the Inspire IV system.
Operating expenses were $14.5 million for the second quarter of 2018, as compared to $9.1 million in the
corresponding prior year period, an increase of 60%. This increase was primarily due to larger employee
headcount associated with the expansion of our U.S. and European sales organization, as well as
increased marketing and general and administrative expenses.
Net loss was $5.9 million in the second quarter of 2018, as compared to $4.8 million in the corresponding
prior year period.
As of June 30, 2018, cash, cash equivalents and short-term investments were $124.0 million. The cash
position reflects the completion of Inspire’s initial public offering on May 7, 2018, raising $112.0 million
of net proceeds after underwriting fees and other expenses.
2018 Financial Outlook
Inspire expects full year 2018 revenue to be in a range of $42.8 million to $44.0 million, representing
growth of 50% to 54% over full year 2017 revenue.
Webcast and Conference Call
Inspire’s management will host an investment community conference call after market close on Tuesday,
August 7, 2018, at 5:00 p.m. Eastern Time to discuss these results and answer questions.
Tuesday, August 7th @ 5:00pm Eastern Time:
Conference ID: 2893271
To listen to a live webcast, please visit the Investors section of the Inspire website at:
www.inspiresleep.com. The webcast replay will be available on the Inspire website for two weeks
following the completion of the call.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides
a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical
facts contained in this press release are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’
‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’
‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar
expressions, although not all forward-looking statements contain these words. Forward-looking
statements in this release include, but are not limited to, Inspire’s financial guidance for full year 2018
and, its expectations regarding the near and long-term growth potential of its business. These forward-
looking statements are based on the current expectations of Inspire’s management and involve known and
unknown risks and uncertainties that may cause Inspire’s actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the
annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the
U.S., future results of operations, financial position, research and development costs, capital requirements
and our needs for additional financing; commercial success and market acceptance of our Inspire therapy;
our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system
or any future products we may seek to commercialize; competitive companies and technologies in our
industry; our ability to expand our indications and develop and commercialize additional products and
enhancements to our Inspire system; our business model and strategic plans for our products, technologies
and business, including our implementation thereof; our ability to accurately forecast customer demand
for our Inspire system and manage our inventory; our ability to expand, manage and maintain our direct
sales and marketing organization, and to market and sell our Inspire system in markets outside of the
U.S.; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to
hire and retain our senior management and other highly qualified personnel; our ability to commercialize
or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in
commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions
affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and
international markets; and our ability to establish and maintain intellectual property protection for our
Inspire therapy and system or avoid claims of infringement. Other important factors that could cause
actual results, performance or achievements to differ materially from those contemplated in this press
release can be found under the caption “Risk Factors” in our quarterly report on Form 10-Q for the
quarter ended March 31, 2018 and our other filings with the Securities and Exchange Commission.
Inspire undertakes no obligation to update or revise any forward-looking statements, even if subsequent
events cause its views to change.